The Pulmonary Hypertension Association (PHA) has committed about $8 million to support cutting-edge research on pulmonary hypertension. PHA has supported more than 75 researchers since the association formed 29 years ago.
PHA grants support promising PH scientists and clinicians who study new methods for early detection, new treatments to prevent the onset of PH, and ultimately a cure.
This award, named for PHA’s first president and CEO, Rino Aldrighetti, was established in 2016 at PHA’s 12th International PH Conference and Scientific Sessions with sponsorship from Actelion Pharmaceuticals U.S. Inc. The program supports the careers of young investigators who likely will make a strong, sustained impact in PH research.
PHA will grant one Aldrighetti Award in 2020. Applications are due Oct. 1.
Learn more about the award and how to apply.
PHA is a launching a new Innovation in PH Research grant. The grant will fund one research and two junior investigator awards. More information will be available in September.
The PVDOMICS study (Redefining Pulmonary Hypertension through Pulmonary Vascular Disease Phenomics) is a partnership between PHA and the National Heart, Lung and Blood Institute at the National Institutes of Health. PVDOMICS uses clinical and biological “omics” data from all pulmonary hypertension (Groups 1 through 5) classifications. The study aims to identify new ways to group PH patients and new biological measurements that ultimately could lead to breakthroughs in diagnosis, outcomes and therapies.
See the PVDOMICS page for details.